Related Experiment Video

Updated: May 9, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Targeted therapy for NSCLC with driver mutations

Gabriele Minuti1, Armida D'Incecco, Federico Cappuzzo

  • 1Medical Oncology Department, Civil Hospital of Livorno, Istituto Toscano Tumori , Viale Alfieri 36, 57100, Livorno , Italy +39 0586 223189 ; +39 0586 223457 ; f.cappuzzo@gmail.com.

Expert Opinion on Biological Therapy
|August 13, 2013
PubMed
Abstract

Insights

Molecular characterization of non-small cell lung cancer (NSCLC) reveals new oncogenes. Targeting these genetic alterations improves treatment strategies and patient outcomes in lung cancer.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Activating mutations in EGFR and ALK rearrangements are key in non-small cell lung cancer (NSCLC).
  • Numerous genetic aberrations (ROS1, RET, MET, HER2, BRAF, KRAS) are identified, primarily in adenocarcinoma.
  • Emerging oncogenic drivers (DDR2, FGFR1, PI3KCA) are characterized in squamous cell lung carcinoma (SCC).

Purpose of the Study:

  • To review the expanding landscape of targetable oncogenes in NSCLC.
  • To summarize genetic alterations and their therapeutic relevance in lung cancer subtypes.
  • To highlight the evolving role of molecular characterization in NSCLC treatment.

Main Methods:

  • Systematic literature review using PubMed.
  • Analysis of published data on NSCLC genomic alterations.
  • Collection of data on identification techniques, prevalence, tumorigenesis role, and targeted agents.

Main Results:

  • EGFR mutations and ALK rearrangements exemplify therapeutic targets in NSCLC.
  • Various genetic aberrations have prognostic and predictive roles, particularly in adenocarcinoma.
  • New oncogenic drivers are identified in SCC, with targeted agents under evaluation.

Conclusions:

  • Oncogenic products are validated targets for drug development in lung cancer.
  • Increased understanding of molecular pathways is transforming NSCLC treatment strategies.
  • Targeted therapies improve disease control, prolong survival, and enhance quality of life for NSCLC patients.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.